Note: Viacyte's revenues are gauged from an analysis of company filings.
Viacyte has actively raised capital from investors. These investors may include private investors, venture capital firms, or other investment vehicles.
December 3, 2018
Complete list of funding rounds and total amounts in the Company Report
Viacyte's Income Statement (based on Industry Averages)
$ Millions (Industry Average)
Viacyte Revenue (Sales)
Cost of Goods Sold
Salaries and wages
Other Operating Expenses
Total Operating Expenses
EBIT (Earnings Before Interest and Taxes)
Trademark applications show the products and services that Viacyte is developing and marketing.
Viacyte doesn't have any recent trademark applications, indicating Viacyte is focusing on
its existing business rather than expanding into new products and markets.
Trademarks may include brand names, product names, logos and slogans.
REGENERATING HEALTH Cells for scientific, laboratory or medical research
ENCAPTRA Drug delivery systems
VIACYTE Scientific research and development for medical and pharmaceutical purposes; scientific research and development related to human diseases and disorders
Patent applications show Viacyte's intellectual property,
its current capabilities and future direction.
Viacyte has applied for 48 patents since 2009.
Viacyte's most recent patent was filed in November 2018 for Cell Compositions Derived From Dedifferentiated Reprogrammed Cells.Disclosed herein are cell culture compositions, for example, pancreatic cell culture compositions, derived from dedifferentiated human reprogrammed pluripotent stem cells, such as induced pluripotent stem (iPS) cells, and methods for producing and using such cell culture compositions.
Complete list of patent applications
Determine whether Viacyte grew or shrank during the last recession. This is useful in estimating the
financial strength and credit risk of the company.
Compare how recession-proof Viacyte is relative to the industry overall.
While a new recession may strike a particular industry, measuring the
industry and company's robustness during the last recession estimates its ability to weather future recessions.
Market Share of Competition: Viacyte vs. Largest Competitors
A competitive analysis shows these companies are in the same general field as Viacyte, even though they may not compete head-to-head.
These are the largest companies by revenue. However, they may not have the largest market share in this industry if they have diversified into other business lines.
The "Competition" section of a business plan or investment memorandum would start by analyzing the information about these companies.
Competitive advantage comes from offering better pricing or superior products/service.
These companies are in the same general field as Viacyte and are rapidly expanding. Companies may grow organically or through acquisition. In some cases apparently high growth rates may be caused by data that weren't available in previous years.